522 related articles for article (PubMed ID: 33813868)
1. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
2. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
Hall EA; Hartzband P; VanderLaan PA; Nishino M
Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
[TBL] [Abstract][Full Text] [Related]
3. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
4. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
[No Abstract] [Full Text] [Related]
5. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of cancer and the benign call rate of afirma gene classifier in
Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
[TBL] [Abstract][Full Text] [Related]
7. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
[TBL] [Abstract][Full Text] [Related]
8. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
9. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
10. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
11. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
[TBL] [Abstract][Full Text] [Related]
13. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
[No Abstract] [Full Text] [Related]
14. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
Figge JJ; Gooding WE; Steward DL; Yip L; Sippel RS; Yang SP; Scheri RP; Sipos JA; Mandel SJ; Mayson SE; Burman KD; Folek JM; Haugen BR; Sosa JA; Parameswaran R; Tan WB; Nikiforov YE; Carty SE
Thyroid; 2021 Nov; 31(11):1673-1682. PubMed ID: 34340592
[No Abstract] [Full Text] [Related]
15. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
Wei S; Veloski C; Sharda P; Ehya H
Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
[TBL] [Abstract][Full Text] [Related]
16. Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance.
Onken AM; VanderLaan PA; Hennessey JV; Hartzband P; Nishino M
Cancer Cytopathol; 2021 Dec; 129(12):947-955. PubMed ID: 34314102
[TBL] [Abstract][Full Text] [Related]
17. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
[TBL] [Abstract][Full Text] [Related]
18. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
19. Clinical diagnostic gene expression thyroid testing.
Steward DL; Kloos RT
Otolaryngol Clin North Am; 2014 Aug; 47(4):573-93. PubMed ID: 25041959
[TBL] [Abstract][Full Text] [Related]
20. An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.
Taccogna S; Papini E; Novizio R; D'Angelo M; Turrini L; Persichetti A; Pontecorvi A; Guglielmi R
Front Endocrinol (Lausanne); 2022; 13():1078019. PubMed ID: 36531453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
